NeoVista, Inc. Announces Initial VIDION... ( Hospital in ...)

NeoVista, Inc. Announces Initial VIDION Shipments

Date:10/30/2009

Hospital in Pisa, Italy is First in World to Receive Revolutionary Epimacular Brachytherapy System

Fremont, CA and Pisa, Italy (PRWEB) October 30, 2009 -- NeoVista, Inc. announced today that the first VIDION® ANV Therapy System for epimacular brachytherapy has been sold and shipped. Unlike anti-VEGF therapy, which requires frequent costly eye injections for an indefinite period of time, NeoVista's novel therapy delivers a one-time dose of radiation via a very commonly used surgical procedure called 'vitrectomy'. NeoVista's epimacular brachytherapy has been shown to be safe and effective in preliminary clinical trials and may offer a cost effective solution to the current treatment burden posed by continuous injections of anti-VEGF therapy.

Dr. Stanislao Rizzo, a world-renowned retinal surgeon from S. Chiara Hospital, Azienda Ospedaliero Universitaria Pisana,Pisa, Italy, said, "We are very excited to be the first hospital to receive this innovative one time treatment procedure, which can help to treat a devastating disease that otherwise requires chronic treatment for an indefinite period of time. NeoVista's targeted epimacular brachytherapy treatment may provide us the ability to improve vision by offering a distinct mechanism of action to conventional anti-VEGF therapy that affects multiple disease pathways, and may dramatically change the patients' quality of life by eliminating frequent eye injections. This promising treatment could very well be a cost-effective alternative to treating neovascular AMD," continued Dr. Rizzo. "Monthly injections can become quite expensive for our health care system, whereas a single procedure will potentially allow our specialists to treat more patients and bring down the costs associated with ongoing treatments while still providing satisfactory outcomes."

Unlike previous radiation therapies for wet AMD, NeoVista's innovat
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:

(Date:12/16/2009)... Inc., developers of the AcceleDent System , ... announced Alison Davies as its new Director of ... spent the last fourteen years of her professional ... nine years as a senior manager with ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO ) ,, ...

(Date:12/16/2009)... -- In a random sampling of wood pallets ... Philadelphia, PA, numerous pallets tested positive for Listeria ... potentially create health hazards for consumers. The ... pallet testing conducted in the Washington-Baltimore area, further ... our nation,s food supply from wood pallets. ,, ...

(Date:12/16/2009)... an amino acid typically found in red meats, ... seeds, can possibly increase the risk of developing ... researchers. , The researchers published their findings, titled ... a mouse model of Alzheimer,s disease," in the ... methionine reaches too high a level, our body ...

(Date:12/16/2009)... conducted through national AAD program ,, ... dies from melanoma, the deadliest form of skin ... successfully treated, if caught early. That,s why thousands ... cancer screenings in their communities through the American ... Program. The program recently reached a milestone - ...

(Date:12/16/2009)... Buchanan, owner of Supreme Ultimate Fitness in Boca ... for his students in the new year. The difference with ... their own prize or against each other. They will be ... Humane Society in Boca Raton, FL. ,, "For ... and February 28, 2010 I will donate $10 to the ...

Breaking Medicine News(10 mins):Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4 Health News:Diet high in methionine could increase risk of Alzheimer's 2 Health News:Dermatologists Reach Skin Cancer Screening Milestone 2 Health News:Dermatologists Reach Skin Cancer Screening Milestone 3 Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2

[0] Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom [0] New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria [0] Diet high in methionine could increase risk of Alzheimer's [0] Dermatologists Reach Skin Cancer Screening Milestone [0] Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter

... alcohol, survey finds, , , FRIDAY, March 27 (HealthDay News) ... drink to excess to impress college men, a new ... than women, research has shown that women have steadily ... decades," study author Joseph LaBrie, an associate professor of ...

... NC Drug-eluting stents were safe and superior to ... among 262,700 "real-world" patients enrolled in a nationwide registry ... Medical Center. , The findings were presented today ... 58th Annual Scientific Session. They also appear online in ...

... children, lower-income families even more vulnerable, aid agency ... Fargo, North Dakota, Christian relief organization World Vision ... and sending staff to assess the needs of ... see their homes flooded and be forced to ...

... Utah, March 27 Nu Skin Enterprises, Inc. (NYSE: ... being donated to villages in Malawi thanks to the company,s ... Since launching the product in January 2008, the company has ... Butter to the Nu Skin Force for Good Foundation,s Seeds ...

... Pet DRx Corporation (Nasdaq: VETS ) a provider ... today announced that the Company will release its financial results ... prior to the opening of the market on Wednesday, April ... conference call on Thursday, April 2, beginning at 2:00 p.m. ...

... Increases First Quarter 2009 Earnings Guidance to a Minimum ... The Providence Service Corporation (Nasdaq: ... and calendar year ended December 31, 2008. Included ... million asset impairment charge related to the Company,s intangible ...

How Much Should Women Drink? It Depends on Who You Ask Drug-eluting stents found safe, superior to bare metal stents Flooding in Fargo: World Vision Sending Supplies and Staff to Help Affected Families Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi Pet DRx to Hold Its Fourth Quarter and Year-End 2008 Financial Results Conference Call Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results

(Date:12/16/2009)... MOUNTAIN VIEW, Calif., Dec. 16 ChemoCentryx, ... patients in a Phase 2 clinical trial of ... to specifically target the CCR1 chemokine receptor for ... CCX354 is a highly potent and selective antagonist ... recruitment of immune cells, such as monocytes and ...

(Date:12/16/2009)... , - MIVI-TRUST ... Total of Over,640 patients Ahead of Schedule ... (Euronext Brussels: THR), a biopharmaceutical company,focused on ... for eye,disease, vascular disease and cancer, announces ... the second Phase III trial evaluating microplasmin ...

(Date:12/15/2009)... DIEGO, Dec. 15 Volcano Corporation (Nasdaq: ... intravascular therapy guidance tools - including Fractional Flow ... and Optical Coherence Tomography (OCT) - designed to ... peripheral vascular disease, announced today the placement of ... s5 family of consoles was first launched in ...

Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2 ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3 ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4 ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5 ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2 ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3 ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4 Volcano Announces Installed Base Growth Milestone 2 Volcano Announces Installed Base Growth Milestone 3 Volcano Announces Installed Base Growth Milestone 4 Volcano Announces Installed Base Growth Milestone 5 Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 1 Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 2 Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 3 Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 4 SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 1 SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 2 SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 3 Athens Consulting Volunteers Time To Habitat For Humanity 59714 1 Athens Consulting Volunteers Time To Habitat For Humanity 59714 2

[0] ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis [0] ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease [0] Volcano Announces Installed Base Growth Milestone

... Novel Heat Shock Protein 90 Inhibitor,Reveal Further ... CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, ... and,MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim,results ... the companies' heat shock,protein 90 (Hsp90) inhibitor, ...

... Study Results Show Antibodies Against Cancer-Causing Virus,Types 16 ... Greater Than Natural,Infection Levels, CHICAGO, June 05, 2007 ... 18 months after the first of a three-dose ... vaccinated with the GlaxoSmithKline,(GSK) cervical cancer candidate vaccine ...

Other Medicine Technology:Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7 Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2 Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3 Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4 Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5

Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Typhus Fever Antibodies, IgG & IgM Tylenol TSH Receptor Antibody Tryptase

NeoVista, Inc. Announces Initial VIDION...( Hospital in ...),Health